Loading
A phase 3 trial of Trastuzumab deruxtecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, now recruiting.
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06899126 by Daiichi Sankyo, with 686 participants planned, started 2025-10-24 and due to reach its primary completion in 2030-04-24. Interventions recorded: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads).
Shares Daiichi Sankyo, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).